Cystic fibrosis–related diabetes (CFRD) is a distinct form of diabetes that develops in people living with cystic fibrosis. It shares features of both type 1 and type 2 diabetes but has a unique underlying cause and clinical course. CFRD occurs when the pancreas becomes progressively scarred by the thick mucus characteristic of cystic fibrosis, impairing the beta cells that produce insulin. Unlike type 1 diabetes, there is no autoimmune attack; unlike type 2, insulin resistance is not the primary problem. Instead, the main defect is a gradual loss of insulin secretion, often combined with some degree of insulin resistance related to chronic inflammation and infections.

CFRD is one of the most common comorbidities in older children and adults with cystic fibrosis. Approximately 20 % of adolescents and 40–50 % of adults with cystic fibrosis develop CFRD. Screening for CFRD is recommended annually after age 10 in individuals with cystic fibrosis because early detection improves lung function, nutritional status, and survival. The prevalence continues to rise as life expectancy for cystic fibrosis increases, making CFRD a major focus in multidisciplinary care.

For additional background on cystic fibrosis and its systemic effects, see the Cystic Fibrosis Foundation’s overview.

Why CFRD Differs from Type 1 and Type 2 Diabetes

Cause and Pathophysiology

Type 1 diabetes is an autoimmune disease in which the immune system mistakenly destroys the insulin-producing beta cells in the pancreas. This destruction is usually rapid, leading to an absolute insulin deficiency. People with type 1 must take insulin from the moment of diagnosis. The autoimmune process involves islet autoantibodies and T-cell-mediated attack, and it is not reversible.

Type 2 diabetes begins with insulin resistance—cells do not respond properly to insulin—and the pancreas initially compensates by producing more insulin. Over time, the beta cells become exhausted and insulin secretion declines. Type 2 is strongly linked to obesity, physical inactivity, and genetic predisposition. In developed countries, excess body fat, particularly visceral adiposity, drives systemic inflammation and impairs glucose uptake in muscle and liver tissue.

CFRD develops from the physical scarring (fibrosis) of the pancreas caused by the cystic fibrosis transmembrane conductance regulator (CFTR) gene defect. The scarring disrupts both the exocrine and endocrine functions of the pancreas. Insulin production gradually decreases, and the liver may also produce too much glucose due to chronic inflammation. Unlike in type 2, insulin resistance is typically mild; unlike in type 1, autoimmune destruction is absent. Instead, beta-cell mass is progressively lost because of the fibrotic environment, and the remaining islets show impaired glucose-stimulated insulin secretion. Additionally, frequent pulmonary infections and systemic inflammation increase cortisol and cytokine levels, which worsen insulin resistance temporarily.

Age of Onset and Clinical Presentation

Type 1 often appears suddenly in childhood or adolescence, though it can occur at any age. The classic triad of polydipsia, polyuria, and weight loss over weeks to months is typical. Type 2 usually develops after age 45, but rising obesity rates have led to increasing diagnoses in younger people. In many cases, type 2 is asymptomatic for years and is detected through routine blood work. CFRD is rare before age 10 and becomes more prevalent in the teenage years and adulthood. The average age at diagnosis is around 20 years, but the diagnosis can be delayed because symptoms are subtle.

The symptoms of CFRD can be subtle and are often mistaken for worsening cystic fibrosis. Common signs include unexplained weight loss, fatigue, frequent lung infections, and a decline in lung function. Classic diabetes symptoms—polydipsia, polyuria, polyphagia—are less prominent or may be masked by the daily demands of managing cystic fibrosis, such as frequent coughing, high-calorie diets, and pancreatic enzyme use. This makes routine screening essential. A sudden drop in body mass index or an increase in pulmonary exacerbations should prompt a formal diabetes evaluation.

Management Strategies

Type 1 diabetes is managed with lifelong insulin therapy, carbohydrate counting, and blood glucose monitoring. Many people use insulin pumps or continuous glucose monitors. The goal is to mimic physiologic insulin secretion as closely as possible while avoiding severe hypoglycemia.

Type 2 diabetes is initially treated with lifestyle modifications (diet, exercise, weight loss) and oral medications such as metformin. Insulin or other injectable agents are added as the disease progresses. The focus is often on reducing caloric intake and increasing physical activity to improve insulin sensitivity.

CFRD is nearly always treated with insulin because oral medications are generally less effective. Insulin therapy helps maintain good blood sugar control while providing the calories needed to counteract malnutrition common in cystic fibrosis. Dietary recommendations for CFRD emphasize high-calorie, high-fat foods (unlike standard diabetes diets) because weight maintenance is a priority. Nutritional management must be coordinated with the cystic fibrosis care team. Oral agents like metformin may occasionally be used as adjuncts but are not first-line; sulfonylureas and GLP-1 receptor agonists are typically avoided due to weight loss effects and lack of evidence.

The Importance of Accurate Diagnosis

Misdiagnosing CFRD as type 1 or type 2 can lead to inappropriate treatment plans that harm overall health. For example, putting a person with CFRD on a calorie-restricted diet (typical for type 2) can worsen malnutrition and accelerate lung decline. Similarly, failing to start insulin promptly can lead to poor glucose control, increased infections, and reduced survival. Conversely, mislabeling CFRD as type 1 may lead to unnecessary autoantibody testing and delay the recognition of cystic fibrosis as the underlying cause.

Diagnosis relies on an oral glucose tolerance test (OGTT), which is the gold standard for CFRD. The test measures blood glucose before and after a glucose load. A 2‑hour glucose level ≥ 200 mg/dL confirms diabetes, but CFRD can also present with fasting hyperglycemia. The CDC’s CFRD resource provides further details on screening guidelines. Intermittent hyperglycemia during acute illness is also common; in such cases, the diagnosis should be confirmed after recovery.

Healthcare providers must also confirm the diagnosis of cystic fibrosis itself (through sweat test or genetic testing) and rule out other types of diabetes. Autoantibody testing can help exclude type 1, while C‑peptide levels and insulin resistance markers differentiate type 2. In CFRD, C-peptide is typically low but not absent, and autoantibodies are negative. Hemoglobin A1c is not reliable for diagnosis due to altered red cell turnover; it is used only for monitoring once diabetes is established.

The Role of CFTR Modulator Therapies

The advent of CFTR modulator therapies—such as ivacaftor, lumacaftor, tezacaftor, and elexacaftor—has transformed the landscape of cystic fibrosis care. These drugs improve CFTR function in people with specific genetic mutations, leading to better lung function, fewer exacerbations, and improved nutritional status. Importantly, modulators also affect the pancreas. By restoring some CFTR activity in pancreatic ductal cells, they can reduce inflammation and scarring, which may slow the progression of endocrine dysfunction.

Studies show that CFTR modulator therapy can improve insulin secretion and glucose tolerance in some individuals with CFRD. However, the effect is not uniform; patients with advanced pancreatic damage may not benefit as much. Modulators also alter energy balance—patients often gain weight and may experience changes in insulin sensitivity. As a result, insulin requirements can change, and close glucose monitoring is essential when starting or adjusting modulator therapy. The interplay between CFTR modulators and CFRD is an active area of research, and ongoing studies aim to determine whether early intervention with modulators can prevent or delay the onset of CFRD altogether.

Complications and Prognosis

Short‑Term Risks

People with CFRD are at risk for both hyperglycemia and hypoglycemia. High blood glucose worsens lung infections by impairing immune function and promoting bacterial growth. Hyperglycemia also impairs neutrophil function and reduces mucociliary clearance, creating a vicious cycle with lung infections. Low blood glucose can occur from insulin therapy combined with missed meals or increased physical activity. Unlike in type 1, diabetic ketoacidosis is rare in CFRD because the pancreas still produces some insulin, but it can occur during severe illness or stress, especially if insulin is withheld.

Long‑Term Complications

Microvascular complications similar to those in type 1 and type 2 diabetes can develop in CFRD, including retinopathy, nephropathy, and neuropathy. Retinopathy prevalence in CFRD increases with diabetes duration; annual eye exams are recommended. Nephropathy is less common but can be accelerated by chronic kidney disease from other cystic fibrosis treatments (e.g., aminoglycosides). Neuropathy symptoms such as peripheral numbness or autonomic dysfunction have been reported, though they are less studied. However, macrovascular complications (heart attack, stroke) appear less common, likely because people with cystic fibrosis often have lower cholesterol and lower blood pressure due to malabsorption and younger age at death.

The most critical long‑term consequence of poorly controlled CFRD is accelerated lung function decline, which is the leading cause of death in cystic fibrosis. Hyperglycemia directly impairs pulmonary function by causing protein glycation, promoting inflammation, and increasing susceptibility to infections like Pseudomonas aeruginosa. Early and aggressive management of CFRD improves outcomes. Studies show that insulin therapy preserves lung function, improves nutritional status, and reduces respiratory exacerbations. The Diabetes UK guide on CFRD summarizes current evidence for treatment benefits.

Special Considerations in Management

Nutrition and Caloric Needs

Unlike standard diabetes nutrition advice, which often restricts carbohydrates and fats, the dietary goal for CFRD is to maintain or increase body weight. People with cystic fibrosis require 120–150 % of the usual caloric intake due to malabsorption and increased energy expenditure from breathing difficulties. Insulin therapy is timed to allow consumption of high‑calorie meals and snacks without causing excessive hyperglycemia. A registered dietitian with expertise in cystic fibrosis should individualize the meal plan. Fat restriction is avoided; instead, patients are encouraged to include healthy fats and protein. Carbohydrates are not eliminated but are balanced with insulin doses. Nutritional supplements may be needed to meet energy needs.

Insulin Regimens

Most individuals with CFRD use a combination of long‑acting (basal) insulin and rapid‑acting (bolus) insulin with meals. Some may do well on premixed insulins, but these are less flexible. Continuous glucose monitoring (CGM) is highly beneficial because it can detect postprandial spikes and nocturnal hypoglycemia, which are common challenges. The cystic fibrosis care team often adjusts insulin doses based on lung function, appetite, and infection status. During acute pulmonary exacerbations, insulin requirements can increase dramatically; conversely, during periods of good health and weight gain, doses may need reduction. Frequent communication between endocrinology and pulmonology teams is essential.

Exercise and Physical Activity

Regular exercise is encouraged for everyone with cystic fibrosis because it improves lung function, bone density, and overall fitness. For those with CFRD, exercise can lower blood glucose, but it also increases the risk of hypoglycemia. Pre‑ and post‑exercise blood glucose checks are recommended. Carbohydrate snacks may be needed to maintain safe glucose levels during prolonged activity. Patients should be taught to recognize and treat hypoglycemia promptly. It is also important to adjust insulin doses on days with increased physical activity.

Screening and Monitoring Recommendations

The Cystic Fibrosis Foundation recommends annual OGTT screening starting at age 10 for all individuals with cystic fibrosis. Screening should be performed when the person is clinically stable (not during an acute pulmonary exacerbation) because illness can cause transient hyperglycemia. If the OGTT is abnormal but not diagnostic, follow‑up testing should occur within six months. Additionally, some centers use continuous glucose monitoring to detect early glucose abnormalities before an OGTT becomes diagnostic.

In addition to OGTT, hemoglobin A1c (HbA1c) is used for monitoring but is less reliable in cystic fibrosis because of altered red blood cell turnover and frequent infections. Fasting glucose and postprandial levels from home glucose monitoring provide more actionable data. A fact sheet from the NIDDK offers more details on monitoring protocols. For patients already on insulin, CGM use is encouraged to fine-tune therapy and reduce hypoglycemia.

Psychosocial and Quality of Life Considerations

Managing CFRD adds another layer of complexity to an already demanding cystic fibrosis treatment regimen. Patients must juggle daily airway clearance, enzymes, inhaled medications, frequent clinic visits, and now insulin injections or pump therapy. This can lead to treatment fatigue, anxiety, and depression. Care teams should screen for emotional distress and provide mental health support. Peer support groups, including online communities specific to CFRD, can be valuable. Educating family members also helps them assist with diabetes management and recognize warning signs. Empowering patients to self-manage with technology like CGM and smart insulin pens can improve confidence and outcomes.

Future Directions and Research

Ongoing research focuses on preventing CFRD through early use of CFTR modulators, understanding the genetic factors that determine who develops CFRD, and developing better glucose monitoring tools. Novel insulin formulations with more predictable absorption are being studied. Additionally, therapies that protect beta-cell function or regenerate pancreatic islets could change the natural history of CFRD. A high-quality review article in Diabetic Medicine summarizes current knowledge and future research priorities. Collaborative registries combining cystic fibrosis and diabetes data will help track outcomes and refine guidelines.

Conclusion

Cystic fibrosis–related diabetes is a unique and challenging condition that requires a different approach than type 1 or type 2 diabetes. Its roots lie in the pancreatic scarring caused by cystic fibrosis, not autoimmune attack or lifestyle factors. Diagnosis often occurs in adolescence or adulthood, and symptoms may be masked by the underlying lung disease. Proper detection through annual OGTT screening is vital, as early insulin therapy can preserve lung function, improve nutrition, and lengthen survival. Management must be integrated with cystic fibrosis care, emphasizing high‑calorie diets, tailored insulin regimens, and close monitoring of both glucose levels and respiratory health.

Awareness among healthcare providers and families is the first step toward better outcomes. By understanding the distinct nature of CFRD, clinicians can avoid misdiagnosis and deliver targeted treatment that addresses the full scope of the patient’s needs. For anyone involved in the care of individuals with cystic fibrosis, staying informed about CFRD is not just beneficial—it is essential. With advances in CFTR modulators and more personalized diabetes management tools, the future for people living with CFRD continues to improve.